ESR1 and breast neoplasm: To investigate this issue, we evaluate all available evidence regarding ER positive and ER-negative breast tumors from a pool of clinical studies and demonstrate that each 10% increment of TILs in breast tumors improves OS in HER2-amplified and TN molecular subtypes but not in the luminal phenotype.